Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Venture Global Inc. Class A common stock (VG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Venture Global Inc. Class A common stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Venture Global Inc. Class A common stock trades at $13.22 (market cap $34.60B). The key difference: Venture Global Inc. Class A common stock is far larger — about 7.1× Travere Therapeutics Inc. Common Stock's market cap, and Venture Global Inc. Class A common stock pays a 1.16% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Venture Global Inc. Class A common stock for 1 Days on average.
| TVTX | VG | |
|---|---|---|
Market Cap | $4.88B | $34.60B |
Volume | 1,668,577 | 11,731,839 |
Sector | Health | Energy |
52-Week High | $67.52 | $17.53 |
52-Week Low | $26.79 | $5.92 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $5.01B | $73.99B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VG trades at $13.84, up 5.41% today, with a bearish technical signal but strong fundamentals including a 21.24% net income margin and 48.13% ROE. Recent earnings have consistently beaten estimates, and the company is expanding LNG capacity to 85 MTPA by 2029, supported by long-term supply deals like the 20-year agreement with ConocoPhillips announced on October 1, 2026.
The stock offers value with a P/E of 10.52 and consensus price target of $16.13, but faces risks from high short interest and negative net cash flow in 2025. Analyst sentiment is bullish with 58% buy ratings, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Venture Global Inc. Class A common stock
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →
